New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

IBD Clinical Trials at a Crossroads

Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.

OCTOBER 22, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

FDA Approves Guselkumab for UC

The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative ...

SEPTEMBER 12, 2024

Study Looks at Infection Risk in Older IBD Patients on Immunosuppressive Therapies

Older adults represent a growing segment of patients with IBD, and several unique factors should be considered when ...

AUGUST 30, 2024

Guselkumab Shows Promise In Crohn’s Disease Trials

Guselkumab induced higher levels of clinical and endoscopic remission than placebo and ustekinumab in the GALAXI ...

AUGUST 23, 2024

Good News for Maintenance Therapies in IBD

Both studies in this month’s The Regueiro Report are about interleukin inhibitors: risankizumab and ...

JULY 16, 2024

FDA Approves Pyzchiva Biosimilar to Stelara

Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...

JULY 3, 2024

FDA Approves Risankizumab for Ulcerative Colitis

The FDA has approved risankizumab (Skyrizi, AbbVie) for patients with moderate to severe ulcerative colitis.

JUNE 26, 2024

Herbal Treatments for Active UC; Guselkumab for Active Crohn’s

This month’s report highlights two studies: two herbal compounds for the treatment of UC and the guselkumab ...

MAY 14, 2024

Anti–IL-23 Agents Effective After Prior UC Treatment Failure

VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...

JANUARY 22, 2024

Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk

In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...

DECEMBER 29, 2023